{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:41:31Z","timestamp":1773319291118,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,7]]},"abstract":"<jats:p>Allergic rhinitis (AR) has considerable impact on the general health of individuals. Therefore, treatment trials should include an evaluation of quality of life. We aimed to determine changes in the quality of life of moderate\/severe AR patients treated with standard treatment in addition to dialyzable leukocyte extract (DLE), a peptide-based immunomodulator. In a prospective, non-controlled trial, DLE was added to the standard treatment regimen for patients with moderate\/severe AR. DLE was administered orally at 2\u2009mg per day for 5 days, followed by 4\u2009mg per week for 5 weeks, and then 2\u2009mg per week for 5 weeks. The primary endpoints were overall improved Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores, domain scores, and individual item scores of 0.5 points or higher. Statistical significance was defined as <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05. Thirty patients (50% female) aged 14 to 60 years old (33.4\u2009\u00b1\u200911.9) were enrolled in this study. The mean overall basal quality of life score was 3.41\u2009\u00b1\u20091.22. After 11 weeks, the mean RQLQ score was 1.74\u2009\u00b1\u20091.09 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .0001; 95% confidence interval [CI], 1.05-2.33), and all the domain scores improved (daily activities <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, 95% CI 0.91\u20132.15, sleep <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, 95% CI 0.9\u20132.26, non-hay fever symptoms <jats:italic toggle=\"yes\">P<\/jats:italic> = .001, 95% CI 0.51\u20131.82, practical problems <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, 95% CI 1.55\u20132.85, nasal symptoms <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, 95% CI 1.36\u20132.67, ocular symptoms <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, 95% CI 1.05\u20132.17, emotional <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, 95% CI 1.23\u20132.55). Each of the 28 individual item scores on the RQLQ showed clinical (minimal important difference [MID] \u2265 0.5) and statistical (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05) improvements. DLE might be a beneficial adjuvant treatment for AR. Our results provide preliminary data for future research.<\/jats:p>\n          <jats:p>Clinical trials registration ID: NCT02506998<\/jats:p>","DOI":"10.1097\/md.0000000000034186","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T12:01:45Z","timestamp":1688731305000},"page":"e34186","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Quality of life in adult patients using dialyzable leukocyte extract for allergic rhinitis"],"prefix":"10.1097","volume":"102","author":[{"given":"Toni Angela","family":"Homberg","sequence":"first","affiliation":[{"name":"Unidad de Servicios Externos e Investigaci\u00f3n Cl\u00ednica (USEIC), Escuela Nacional de Ciencias Biol\u00f3gicas, Instituto Polit\u00e9cnico Nacional, Ciudad de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Lara","sequence":"additional","affiliation":[{"name":"Unidad de Servicios Externos e Investigaci\u00f3n Cl\u00ednica (USEIC), Escuela Nacional de Ciencias Biol\u00f3gicas, Instituto Polit\u00e9cnico Nacional, Ciudad de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consuelo","family":"Andaluz","sequence":"additional","affiliation":[{"name":"Unidad de Servicios Externos e Investigaci\u00f3n Cl\u00ednica (USEIC), Escuela Nacional de Ciencias Biol\u00f3gicas, Instituto Polit\u00e9cnico Nacional, Ciudad de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Cervantes-Trujano","sequence":"additional","affiliation":[{"name":"Unidad de Servicios Externos e Investigaci\u00f3n Cl\u00ednica (USEIC), Escuela Nacional de Ciencias Biol\u00f3gicas, Instituto Polit\u00e9cnico Nacional, Ciudad de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Mart\u00edn","family":"Hern\u00e1ndez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Unidad de Servicios Externos e Investigaci\u00f3n Cl\u00ednica (USEIC), Escuela Nacional de Ciencias Biol\u00f3gicas, Instituto Polit\u00e9cnico Nacional, Ciudad de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia Mayra","family":"P\u00e9rez-Tapia","sequence":"additional","affiliation":[{"name":"Unidad de Desarrollo e Investigaci\u00f3n en Bioterap\u00e9uticos (UDIBI), Escuela Nacional de Ciencias Biol\u00f3gicas, Instituto Polit\u00e9cnico Nacional, Ciudad de Mexico, Mexico"},{"name":"Departamento de Inmunolog\u00eda, Escuela Nacional de Ciencias Biol\u00f3gicas, Instituto Polit\u00e9cnico Nacional, Ciudad de Mexico, Mexico"},{"name":"Laboratorio Nacional para Servicios Especializados de Investigaci\u00f3n, Desarrollo e Innovaci\u00f3n (I+D+i) para Farmacoqu\u00edmicos y Biotecnol\u00f3gicos, LANSEIDI-FarBiotec-CONACyT, Ciudad de Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Carmen","family":"Jim\u00e9nez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Facultad de Medicina, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Ciudad de Mexico, Mexico"},{"name":"Departamento de Inmunolog\u00eda, Unidad de Investigaci\u00f3n, Instituto de Oftalmolog\u00eda Fundaci\u00f3n \u201cConde de Valenciana\u201d, Ciudad DE Mexico, Mexico."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines \u2013 2016 revision.","volume":"140","author":"Bro\u017cek","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"980515","DOI":"10.3389\/falgy.2022.980515","article-title":"Control of allergic rhinitis in four Latin American countries: Rinola study.","volume":"3","author":"Silva","year":"2022","journal-title":"Front Allergy"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1398-9995.2008.01884.x","article-title":"Global map of the prevalence of symptoms of rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) phase three.","volume":"64","author":"A\u00eft-Khaled","year":"2009","journal-title":"Allergy"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41533-020-00195-8","article-title":"Perception and control of allergic rhinitis in primary care.","volume":"30","author":"Demoly","year":"2020","journal-title":"npj Prim Care Respir Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2500\/aap.2021.42.210052","article-title":"Interaction effects of asthma and rhinitis control on work productivity and activity impairment: a cross-sectional study.","volume":"42","author":"Zhu","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jaip.2017.09.002","article-title":"Impact of rhinitis on work productivity: a systematic review.","volume":"6","author":"Vandenplas","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaip.2019.11.008","article-title":"Allergic endotypes and phenotypes of asthma.","volume":"8","author":"Akar-Ghibril","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1398-9995.2011.02590.x","article-title":"How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement: an ARIA-GA2LEN statement on immunotherapy.","volume":"66","author":"Bousquet","year":"2011","journal-title":"Allergy"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41572-020-00227-0","article-title":"Allergic rhinitis.","volume":"6","author":"Bousquet","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jaip.2021.03.029","article-title":"Immunological responses and biomarkers for allergen-specific immunotherapy against inhaled allergens.","volume":"9","author":"Shamji","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.job.2019.02.001","article-title":"Mechanisms underlying the induction of regulatory T cells by sublingual immunotherapy.","volume":"61","author":"Tanaka","year":"2019","journal-title":"J Oral Biosci"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejps.2015.04.010","article-title":"The similarity question for biologicals and non-biological complex drugs.","volume":"76","author":"Crommelin","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jpba.2013.09.004","article-title":"Batch-to-batch reproducibility of TransferonTM.","volume":"88","author":"Medina-Rivero","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"569039","DOI":"10.3389\/fphar.2020.569039","article-title":"Sequencing analysis and identification of the primary peptide component of the dialyzable leukocyte extract \u201cTransferon Oral\u201d: the starting point to understand its mechanism of action.","volume":"11","author":"Vallejo-Castillo","year":"2020","journal-title":"Front Pharmacol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"4097642","DOI":"10.1155\/2016\/4097642","article-title":"Early differentiation of Human CD11c+NK Cells with \u03b3\u03b4 T Cell activation properties is promoted by dialyzable leukocyte extracts.","volume":"2016","author":"Ram\u00edrez-Ram\u00edrez","year":"2016","journal-title":"J Immunol Res"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/267871","article-title":"Effect of selective serotonin reuptake inhibitors and immunomodulator on cytokines levels: an alternative therapy for patients with major depressive disorder.","volume":"2013","author":"Hernandez","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0192-0561(98)00031-9","article-title":"Comparative study of transfer factor and acyclovir in the treatment of herpes zoster.","volume":"20","author":"Estrada-Parra","year":"1998","journal-title":"Int J Immunopharmacol"},{"key":"R19-20250504","first-page":"134","article-title":"Indications, usage, and dosage of the transfer factor.","volume":"54","author":"Berr\u00f3n-P\u00e9rez","year":"2007","journal-title":"Rev Alerg Mex"},{"key":"R20-20250504","first-page":"56","article-title":"[Allergic rhinitis update and its impact on asthma (ARIA 2008). Latin American perspective].","volume":"56","author":"Cagnani","year":"2009","journal-title":"Rev Alerg Mex"},{"issue":"2 Pt 1","key":"R21-20250504","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0091-6749(99)70380-5","article-title":"Validation of the standardized version of the rhinoconjunctivitis quality of life questionnaire.","volume":"104","author":"Juniper","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0091-6749(96)70135-5","article-title":"Interpretation of rhinoconjunctivitis quality of life questionnaire data.","volume":"98","author":"Juniper","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/alr.23015","article-title":"Combined medical therapy in the treatment of allergic rhinitis: systematic review and meta-analyses.","volume":"12","author":"Chitsuthipakorn","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"P5","DOI":"10.1186\/1939-4551-7-S1-P5","article-title":"Poster 1008: dialyzable leukocyte extracts as adjuvant treatment for allergic rhinitis.","volume":"7","author":"Homberg","year":"2014","journal-title":"World Allergy Organ J"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2500\/ajra.2017.31.4465","article-title":"Quality-of-life outcomes in patients who underwent subcutaneous immunotherapy and sublingual immunotherapy in a real-world clinical setting.","volume":"31","author":"Schwanke","year":"2017","journal-title":"Am J Rhinol Allergy"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/all.15207","article-title":"Determining the minimal important differences in the RQLQ score with grass and tree allergy immunotherapy versus placebo in adults with moderate-to-severe allergy.","volume":"77","author":"Blaiss","year":"2022","journal-title":"Allergy"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ejcn.2014.13","article-title":"Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study).","volume":"68","author":"Costa","year":"2014","journal-title":"Eur J Clin Nutr"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaci.2018.07.041","article-title":"Rhinitis in children and adolescents with asthma: ubiquitous, difficult to control, and associated with asthma outcomes.","volume":"143","author":"Togias","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000498861","article-title":"Multimorbidity in asthma, allergic conditions and COPD increase disease severity, drug use and costs: the Finnish pharmacy survey.","volume":"179","author":"Jantunen","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1159\/000342991","article-title":"Impact of allergic rhinitis symptoms on quality of life in primary care.","volume":"160","author":"Bousquet","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jaip.2019.01.015","article-title":"Validation of patient-reported outcomes for clinical trials in allergic rhinitis: a systematic review.","volume":"7","author":"Calder\u00f3n","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4236\/pp.2015.62009","article-title":"The adverse event profile in patients treated with transferon TM; (Dialyzable Leukocyte Extracts): a preliminary report.","volume":"06","author":"Homberg","year":"2015","journal-title":"PP"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:02:17Z","timestamp":1746324137000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":31,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034186","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}